NY-ESO-1 and CTp11 expression may correlate with stage of progression in melanoma
NY-ESO-1 and CTp11 expression may correlate with stage of progression in melanoma
复制标题
DOI：
10.1006/jsre.2001.6148
复制
发表时间：
2001-06-15
影响因子：
2.2
通讯作者：
Shih, WC
中科院分区：
文献类型：
--
作者：
Goydos, JS;Patel, M;Shih, WC
背景。当肿瘤细胞扩散到原发部位以外时，它们的基因表达会发生变化，这可能是可检测到的，对微分期是有用的。癌/睾丸（CT）抗原是一个蛋白质家族，包括MAGE 1-3、NY-ESO-1、SSX 1-5和其他可能是微分期黑色素瘤的标记物。许多肿瘤类型都能产生CT抗原，但除睾丸外的正常组织很少产生。一种CT抗原CTp11在转移性黑色素瘤细胞系中表达，而在非转移性黑色素瘤细胞系中不表达。我们通过研究不同进展阶段黑色素瘤样本中CTp11和NY-ESO-1的表达来验证这一发现。材料和方法。我们收集了20例原发性、22例局部和10例远处转移性黑色素瘤样本。我们提取总RNA，反转录得到cDNA，利用引物进行pcr扩增，检测p-actin、酪氨酸酶、MART-1、NY-ESO-1和CTp11。聚合酶链反应产物在溴化乙酯染色琼脂糖凝胶上分离，紫外透照显示。所有样本均呈p-肌动蛋白和MART-1阳性，除两个样本外，其余样本均呈酪氨酸酶阳性，证实了RNA完整性和黑色素瘤的存在。27份样本NYESO-1、CTp11或两者均阳性。CTp11倾向于在原发性黑色素瘤中表达，NY-ESO-1倾向于在转移样本中表达（P < 0.02）。CTp11和NY-ESO-1在黑色素瘤不同进展阶段的表达分布差异有统计学意义。NY-ESO-1可能是较晚期疾病的标志物，CTp11可能是较不晚期疾病的标志物。(C) 2001学术出版社。
Background. As tumor cells spread beyond their primary site they undergo changes in their gene expression that may be detectable and useful for microstaging. The cancer/testis (CT) antigens are a family of proteins that include MAGE 1-3, NY-ESO-1, SSX 1-5, and others that are potential markers for microstaging melanoma. CT antigens are produced by many tumor types but few normal tissues other than testis. One CT antigen, CTp11, was shown to be expressed by metastasizing melanoma cell lines but not by nonmetastasizing variants. We tested this finding by studying the expression of CTp11 and NY-ESO-1 by melanoma samples from different stages of progression.Materials and methods. We collected 20 primary, 22 locoregional, and 10 distant metastatic melanoma samples. We extracted total RNA, and reverse transcription yielded cDNA, which was PCR-amplified using primers to detect p-actin, tyrosinase, MART-1, NY-ESO-1, and CTp11. The PCR products were separated on ethidium bromide-stained agarose gels and visualized by UV transillumination.Results. All samples were positive for p-actin and MART-1 and all but two were positive for tyrosinase, confirming RNA integrity and the presence of melanoma. Twenty-seven samples were positive for NYESO-1, CTp11, or both. CTp11 tended to be expressed by primary melanomas and NY-ESO-1 by metastatic samples (P < 0.02).Conclusions. There is a statistically significant difference in the distribution of the expression of CTp11 and NY-ESO-1 in melanoma from different stages of progression. NY-ESO-1 may be a marker of more advanced disease and CTp11 of less advanced disease. (C) 2001 Academic Press.